Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
US10172887B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10172887-B2 |
| Application number | US-201715606951-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 26, 2017 |
| Priority date | Sep 4, 2014 |
| Publication date | Jan 8, 2019 |
| Grant date | Jan 8, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes (“MILs”). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs.
First claim
Opening claim text (preview).
What is claimed: 1. A composition comprising a population of ex vivo hypoxic-activated, normoxic expanded marrow infiltrating lymphocytes, wherein about 60% to about 100% of the population express CD3 and at least 21% of the population express 4-1BB. 2. The composition of claim 1 , wherein about 70% to about 100% of the population express CD3. 3. The composition of claim 1 , wherein about 75% to about 100% of the population express CD3. 4. The composition of claim 1 , wherein about 80% to about 100% of the population express CD3. 5. The composition of claim 1 , wherein about 85% to about 100% of the population express CD3. 6. The composition of claim 1 , wherein about 89% to about 100% of the population express CD3. 7. The composition of claim 1 , wherein at least 70% of the population express CD3. 8. The composition of claim 1 , wherein at least 75% of the population express CD3. 9. The composition of claim 1 , wherein at least 80% of the population express CD3. 10. The composition of claim 1 , wherein at least 85% of the population express CD3. 11. The composition of claim 1 , wherein at least 89% of the population express CD3. 12. The composition of claim 1 , wherein the population express CD4. 13. The composition of claim 1 , wherein the population express CD8. 14. The composition of claim 1 , wherein about 21% to about 100% of the population express 4-1BB. 15. The composition of claim 1 , wherein about 25% to about 100% of the population express 4-1BB. 16. The composition of claim 1 , wherein at least 25% of the population express 4-1BB. 17. The composition of claim 1 , wherein at least 30% of the population express 4-1BB. 18. The composition of claim 1 , wherein at least 35% of the population express 4-1BB. 19. The composition of claim 1 , wherein the population is obtainable from a bone marrow sample obtained from a subject having cancer by: (a) culturing the bone marrow sample with an anti-CD3 antibody and an anti-CD28 antibody in a hypoxic environment of about 1% to about 3% oxygen to produce activated marrow infiltrating lymphocytes; and (b) culturing the activated marrow infiltrating lymphocytes in a normoxic environment in the presence of IL-2 to produce the composition.
Assignees
Inventors
Classifications
Interleukin-2 (IL-2) · CPC title
- A61P35/00Primary
Antineoplastic agents · CPC title
the cells being hematopoietic, bone marrow derived or blood cells · CPC title
Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N5/0647, C12N5/0663) · CPC title
Proteins not provided for elsewhere · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10172887B2 cover?
- In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes (“MILs”). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering…
- Who is the assignee on this patent?
- Univ Johns Hopkins
- What technology area does this patent fall under?
- Primary CPC classification A61P35/00. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).